Skip to main content
Clinical Trials/ACTRN12618001829202
ACTRN12618001829202CompletedPhase 2

TARGET Protein Feasibility Study: a prospective, blinded, parallel group, randomised controlled trial to assess the feasibility of conducting a phase III trial of protein targets in critically ill adults

Professor Marianne Chapman0 sites120 target enrollmentStarted: November 9, 2018Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
120

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • 1.Aged greater than or equal to 18 years old
  • 2.Receiving invasive mechanical ventilation
  • 3.About to commence EN or EN commenced within the previous 12 hours
  • 4.Expected to be receiving EN in ICU beyond the calendar day following randomisation

Exclusion Criteria

  • 1.Expected to be receiving any oral nutrition before the calendar day following randomisation
  • 2.Any EN or PN received for >12 hours in any ICU admission in this hospital episode
  • 3.Previously enrolled in this study
  • 4.Treating clinician considers the EN goal rate (i.e. 1ml/kg of ideal body weight (IBW) per hour) to be clinically contraindicated e.g. requirement for fluid restriction
  • 5.Treating clinician considers that either dose of protein delivered in this study is unsuitable for the patient.
  • 6.Requirement for specific nutritional therapy as determined by the treating doctor or dietitian i.e. protocol EN not considered to be in the best interest of the subject

Investigators

Sponsor
Professor Marianne Chapman

Similar Trials